52 completed, 7 recruiting, 5 terminated, 4 active not recruiting. 21 Phase 3, 14 Not applicable, 11 Phase 4, 9 Phase 2, 8 Phase 1.
Follow gadobutrol: new trials by email Literature Review of gadobutrol trials Research Report on gadobutrol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast Gadobutrol - Healthy Volunteers | Phase 1 | Not yet recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 15 | 2026-10-29 | 2026-10-26 |
| Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease MRI Scan, VUEWAY, Gadavist - Leptomeningeal Disease | Not applicable | Recruiting | M.D. Anderson Cancer Center | 40 | 2026-06-10 | 2026-06-18 |
| A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL, MRI Scan, Gadobutrol - Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion | Phase 2 / Phase 3 | Recruiting | GE Healthcare | 640 | 2026-04-01 | 2026-06-29 |
| A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions HRS-9231 Injection, Gadobutrol Injection, Magnetic Resonance Imaging (MRI) - For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions | Phase 3 | Completed | Shanghai Shengdi Pharmaceutical Co., Ltd | 250 | 2025-11-17 | 2026-06-30 |
| A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions HRS-9231 Injection, Gadobutrol Injection, Magnetic Resonance Imaging (MRI) - For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS) | Phase 3 | Completed | Shanghai Shengdi Pharmaceutical Co., Ltd | 309 | 2025-11-14 | 2026-06-30 |
| Randomized Comparison of Contrast Agents Gadopiclenol and Gadobutrol in the Workup of Incidental Renal and Adrenal Findings Gadobutrol (Gadovist/Gadavist), Gadopiclenol - Suspect Renal and Adrenal Imaging Findings | Phase 4 | Terminated | Insel Gruppe AG, University Hospital Bern | 17 | 2025-08-18 | 2026-10-16 |
| The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study Quantitative Myocardial Blood Flow Evaluation, Qualitative Myocardial Blood Flow Evaluation, Gadavist - Ischemic Heart Disease (IHD), Cardiac Magnetic Resonance Imaging | Not applicable | Recruiting | Brigham and Women's Hospital | 1000 | 2025-06-27 | 2026-09-01 |
| Gadopiclenol vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI (Magnetic Resonance Imaging) Gadopiclenol, Gadobutrol (Gadavist, BAY86-4875) - Contrast Enhanced Images vs. Non-contrast Images, Gadopiclinol Enhanced Images vs. Gadobutrol Enhanced Images | Phase 4 | Recruiting | UConn Health | 10 | 2025-03-25 | 2026-04-28 |
| A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions HRS-9231, Gadobutrol - For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions | Phase 2 | Not yet recruiting | Jiangsu HengRui Medicine Co., Ltd. | 78 | 2024-12-01 | 2024-12-12 |
| A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine - Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology | Phase 3 | Completed | Bayer | 410 | 2023-07-24 | 2026-08-20 |
| A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine - Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology | Phase 3 | Completed | Bayer | 321 | 2023-07-24 | 2026-10-08 |
| Evaluation of Gadopiclenol for Magnetic Resonance Imaging (MRI) in Japanese Adults and Children Gadopiclenol, Comparator (gadobutrol) - Lesion in Body Region, CNS Lesion | Phase 3 | Completed | Guerbet | 240 | 2023-07-21 | 2026-06-25 |
| PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer Fluorine F 18 DCFPyL, Gadobenate Dimeglumine, Gadobutrol - Prostate Carcinoma | Phase 2 | Withdrawn | Northwestern University | 2023-06-17 | 2025-10-21 | |
| MR Image Synthesis With Low Gadobutrol Dose and AI SubtleGAD, Gadobutrol - Enhancing Brain Lesions | Phase 1 | Completed | Subtle Medical | 60 | 2023-06-16 | 2025-09-02 |
| Phenotyping Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) by Intravesical Contrast Enhanced - Magnetic Resonance Imaging (ICE-MRI) Bladder Permeability Assay Ferumoxytol, Gadobutrol - IC - Interstitial Cystitis | Completed | Christopher J Chermansky, MD | 7 | 2023-03-29 | 2026-07-10 | |
| A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting Gadobutrol (Gadavist/Gadovist, BAY86-4875) - Contrast Enhancement in Magnetic Resonance Imaging | Completed | Bayer | 1602 | 2022-11-03 | 2024-04-01 | |
| Acceleration of the Kinetics of Diffusion of Gadolinium in the Perilymphatic Structures of the Inner Ear. Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL) - Inner Ear ; Meniere's Disease; Imaging | Not applicable | Unknown | University Hospital, Grenoble | 80 | 2021-07-31 | 2021-07-02 |
| Novel Imaging Technique to Assess Gynecologic Cancer Gadobutrol, MRI - Gynecologic Cancer | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 24 | 2021-05-13 | 2026-04-02 |
| Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain - Motor Function, Cognitive Function | Phase 4 | Recruiting | Guerbet | 2076 | 2021-03-24 | 2026-01-22 |
| Dotarem vs Gadobutrol Contrast for Breast MRI Gadoterate meglumine, Gadobutrol - Breast Diseases | Phase 4 | Completed | University of Massachusetts, Worcester | 300 | 2021-03-01 | 2026-03-17 |
Showing 20 of 75. Sign in to see all of them.
Coronary Artery Disease (5) · Brain Neoplasms (4) · Breast Neoplasms (4) · Central Nervous System Diseases (3) · Neoplasms (3) · Prostatic Neoplasms (3) · Brain Diseases (2) · Carcinoma, Hepatocellular (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Alzheimer Disease (1) · Arthritis, Rheumatoid (1) · Astrocytoma (1) · Atrial Fibrillation (1) · Breast Diseases (1)
Bayer (28) · Guerbet (4) · M.D. Anderson Cancer Center (4) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Bracco Diagnostics, Inc (2) · British Columbia Cancer Agency (2) · Cedars-Sinai Medical Center (2) · GlaxoSmithKline (2) · Northwestern University (2) · Shanghai Shengdi Pharmaceutical Co., Ltd (2) · Brigham and Women's Hospital (1) · Christopher J Chermansky, MD (1) · Fundacion Clinic per a la Recerca Biomédica (1) · GE Healthcare (1) · Insel Gruppe AG, University Hospital Bern (1)
United States (43) · Germany (19) · South Korea (14) · Canada (13) · China (11) · France (10) · Italy (10) · Japan (9) · Switzerland (9) · Argentina (8) · Poland (8) · Austria (7) · United Kingdom (6) · Colombia (5) · Czechia (5)
Gianpaolo Pirovano, MD (2) · Adam Liebert, Prof. (1) · Andreas Christe, Prof. Dr. med. (1) · Andrei Iagaru, MD (1) · Bonnie Joe, MD, PhD (1) · Christina L Goldstein, MD (1) · Christopher Chermansky, MD (1) · Daniel S Reich, M.D. (1) · Debiao Li, PhD (1) · Dipan Shah, MD (1) · Edward M Schaeffer, MD/PhD (1) · H WM van Laarhoven, M.D., Ph.D. (1) · Jae Mo Park, PhD (1)
PMID 26840494, PMID 35462754, PMID 19858730, PMID 21467949, PMID 21964696, PMID 22409261, PMID 23455520, PMID 23681501, PMID 24110368, PMID 25300984, PMID 26405167, PMID 26956325, PMID 30232584, PMID 31236756, PMID 34133205, PMID 36729404
2009 (2), 2005 (1), 2008 (1), 2018 (1), 2019 (1), 2025 (1), P30CA014089 (1), P30CA016672 (1), P30CA060553 (1), R01CA116182 (1), R01CA249016 (1), R01HL124649 (1), R44DK108397 (1), U01CA225427 (1)